OSU/ITC DECEMBER 26, 1996
LICENSE AGREEMENT
This agreement is between The Ohio State University, an instrumentality of
the State of Ohio, and The Ohio State University Research Foundation, a
non-profit corporation of Ohio having a principal place of business at 0000
Xxxxx Xxxx, Xxxxxxxx, Xxxx 00000-0000 (hereinafter collectively "OSU") and
ImmunoTherapy Corporation, with a principal place of business at 000 Xxxxxxx
Xxxxxx Xxxx, Xxxxx 000, Xxxxxxx, Xxxxxxxxxx, 00000-0000 (hereinafter "ITC").
WHEREAS, OSU has rights to certain inventions by Xxxxxxxxx Xxxxxx X. Xxxxxxx
listed in Appendix A of this Agreement covering the use of modified proteins
for the care and treatment, detection, diagnosis and/or prevention of various
conditions and maladies (hereinafter the "TECHNOLOGY"), and
WHEREAS, on March 12, 1996, the parties hereto entered into a license
agreement granting ITC certain exclusive rights, patents and know how owned
or controlled by OSU and elating to the use of modified hCG in the treatment,
detection, diagnosis and/or prevention of cancer, and
WHEREAS, ITC is interested expanding its rights by licensing TECHNOLOGY for
the purpose of providing commercial products to the marketplace using
modified hCG for the treatment, detection, diagnosis and or prevention of
diseases other than cancer, and to use non-hormone proteins for the
treatment, detection, diagnosis and/or prevention of cancer
WHEREAS, OSU is interested in having the commercial products made available
to the public for the public good;
NOW, THEREFORE, in consideration of the mutual covenants and agreements
herein contained, the parties intending to be legally bound do hereby agree
as follows:
1.0 The following definitions shall, unless the context clearly
indicates some other meaning, apply throughout this License and any
appendices, schedules and amendments thereto:
1.1 "Other Hormones" are all hormones except human chorionic
gonadotropin (hCG), Gonadotropin Releasing Hormone (GnRH) and Gastrin.
1.2 "Subject Product" is any composition covered by a claim of a
Licensed Patent and capable of inducing or enhancing the potential for immune
response to hCG or non-hormonal antigens.
1.3 "Subject Vaccine" is a Subject Product that is fully formulated so
as to be practically effective and safe for administration to subjects.
1.4 "Subject Service" is a method or process covered by a claim of a
Licensed Patent and employed in the development, testing, manufacture or use
of a Subject Product.
1
OSU/ITC DECEMBER 26, 1996
1.5 "Licensed Patents" are the patents and patent applications listed
in Appendix A and, all other patents and patent applications for past and
future inventions of Xx. Xxxxxxx and coworkers under his direction first
reduced to practice before the expiration or earlier termination of this
License, insofar as such patent or application is owned or controlled by OSU
during the term of the License, unless rejected by ITC as Licensed Patents by
written notice to OSU within 30 days after receiving notice from OSU of any
such other patent or patent application or of OSU's intention to prepare and
file such application. Specifically excluded are certain Canadian patents
owned personally by Xx. Xxxxxx X. Xxxxxxx. Except as may be otherwise
provided herein, while any application included within the definition of
Licensed Patents is pending, it will be treated under this License as if it
were an issued patent in the jurisdiction(s) for which it is pending.
1.6 "Licensed Product", "Licensed Vaccine" and "Licensed Service" are
Subject Product, Subject Vaccine and Subject Service, respectively, insofar
as covered by the within License.
1.7 "Licensed Know How" is the technical data, specifications,
processes, manufacturing methods and techniques, and clinical data owned or
controlled by OSU during the term of the License which relate to or are
reasonably usable in the development, manufacture use or sale of a Subject
Product, a Subject Vaccine, or a Subject Service.
1.8 "Net Sales" are ITC's gross xxxxxxxx for Licensed Products,
Licensed Services and Licensed Vaccines produced hereunder less the sum of
the following:
a) discounts allowed in the amounts customary in the trade;
b) sales tax, tariff duties and or use taxes directly imposed and with
reference to particular sales;
c) outbound transportation prepaid or allowed;
d) amounts allowed or credited on returns;
e) sales for research, development and product testing;
No deductions shall be made for commissions paid to individuals whether
they be with independent sales agencies or regularly employed by ITC and on
its payroll, or for cost of collections. License Products, Licensed Vaccine
and Licensed Service shall be considered "sold" when billed out or invoiced.
1.9 "Field of Use" shall be the use of Subject Products and Subject
Service in the case of the non-hormonal antigens for the treatment,
detection, diagnosis and/or prevention of cancer and in the case of hCG, for
any other application except cancer (which is covered in the agreement of
March 12, 1996), and except for fertility control.
1.10 "Active Development" shall mean that ITC or ITC licensee is funding
a program at a level of two hundred thousand dollars ($200,000) per year for
the treatment, detection, diagnosis and/or prevention of cancer with a
specific antigen or that regulatory approval has been given by the U.S.
Federal Food and Drug Agency or its equivalent in another country. Such
program shall be recognized by OSU and ITC in writing and attached to
Appendix B.
2
OSU/ITC December 26, 1996
1.11 "Developing Countries" shall mean all countries in Africa, Asia and
Oceania except Australia, Israel, Japan, New Zealand and South Africa and all
countries of the Americans except Argentina, Canada and the United States of
America.
2. OSU hereby grants to ITC a license ("License") with the right to
sublicense others, under Licensed Patents and Licensed Know How to develop,
test, manufacture, export, import, sell and use Subject Products and Subject
Services in the Field of Use, which license, except insofar as otherwise
provided herein, --
a) is, with respect to each Licensed Patent, for the full term thereof
remaining at the effective date of this Agreement or at such later time as it
becomes a Licensed Patent hereunder,
b) is exclusive with respect to non-hormonal antigens and to hCG in
the Field of Use, but does not preclude OSU from licensing Licensed Patents
and Licensed Know How to others for other purposes, from practicing Licensed
Patents or Licensed Know How for any research or educational purpose, and is
subject to rights of WHO to a non-exclusive royalty-free license to hCG
applications in the public sector under Licensed Patents and Licensed Know
How with the right to sub-license non-profit organizations and governments in
Developing Countries;
c) includes the right of ITC to sublicense others, provided that ITC
remains responsible for all payments, representations, and undertakings and
promises made herein or hereunder by ITC to or for the benefit of OSU or WHO;
and
d) includes access by ITC to all Licensed Know How, data and other
information developed by Xx. Xxxxxxx and coworkers under his general
direction during the term of this license through their activities at or on
behalf of OSU and relating to the development, testing, manufacture or use of
Licensed Product, together with the right of ITC to use such Licensed Know
How, data and other information in developing, testing, manufacturing and
using Licensed Product for the ultimate purpose of preventing or treating
cancer, subject to any rights of others in such data and other information
and to obligations of confidentiality where appropriate.
3.0 ITC shall grant OSU twenty-five thousand (25,000) shares of ITC
preferred Class A Stock.
3.1 ITC will pay OSU royalties of five percent (5%) of Net Sales by ITC
in the U.S. of Licensed Product or Licensed Service. However, no royalty will
be due hereunder in respect of any transaction or activity unless such
transaction or activity would, in the absence of the within License,
constitute an infringement of a claim of a Licensed Patent, where neither
such claim nor Licensed Patent has (i) expired, (ii) been abandoned,
canceled, disclaimed or dedicated with prejudice, or (iii) been finally and
unappealable declared unpatentable, invalid or unenforceable. Any royalties
accruing hereunder solely by virtue of one or more applications pending that
are included within the definition of Licensed Patents shall be deposited in
escrow for the benefit of OSU, and will be paid to OSU upon notice to ITC
that a patent has issued on such an application.
3
3.2 ITC will pay OSU a royalty of two percent (2%) of Net Sales in the
U.S. of any Licensed Product and Licensed Service on which ITC paid a royalty
during the life of the Licensed Patents in the U. S., said royalty being for
use of the Licensed Know How and to commence only upon expiration of the last
Licensed Patent in the U. S. and to run for ten (10) years from such
expiration date.
3.3 ITC will pay OSU a royalty of two percent (2%) of Net Sales by ITC
in the countries which are members of the European Economic Community (EEC)
on December 31, 1995 of any Licensed Product or Licensed Service on which
Licensed Product or Licensed Service ITC paid a royalty on sales in the U. S.
during the life of the Licensed Patents in the U. S., said obligation to begin
on the effective date of this License and run for thirty (30) years; said
royalty to be for both the Licensed Know How and for any Licensed Patent
which has or will issue in the EEC.
3.4 ITC will pay OSU twenty five percent (25%) of any royalties
received by ITC from sublicenses of the Licensed Patents and/or Licensed Know
How in the U. S., EEC or Korea.
3.5 All royalties and other payments due to OSU under this License will
be paid by ITC to OSU within 60 days after the close of each calendar quarter
with respect to such sales in that quarter. Such royalties will be due with
respect to each sale of any particular unit of Licensed Product, or of
Licensed Service in respect of such unit, in any form, through the first sale
of such unit, or of Licensed Service resulting in the production or use of
such unit, in the form of a Licensed Vaccine, to a buyer not affiliated with
either ITC or the seller in such transaction, provided that any royalties
paid to OSU with respect to prior sales of such unit, or of Licensed Service
in respect of such unit, in any form, will be offsettable against royalties
that would otherwise be payable to OSU hereunder with respect to later sales
of the same unit, or of Licensed Service in respect of such same unit, in any
form, and further provided that the maximum cumulative royalty due and
payable to OSU hereunder with respect to any such unit, in all forms, shall
not exceed five percent (5%) of the amount of said first sale of such unit,
or of Licensed Service involving such unit, in the form of a Licensed
Vaccine, to an unaffiliated buyer.
3.6 ITC will submit to OSU a concise written statement setting forth
the determination of the amount of royalties payable to accompany any payment
rendered but in any event not later than 60 days after the end of each
calendar quarter in which any royalties have accrued hereunder. ITC will
prepare records reasonably adequate to accurately determine the amount of
royalties payable to OSU hereunder, make such records available for
reasonable inspection and analysis by OSU, and retain such records for at
least 3 years after the end of any period in which royalties may have accrued
or until any questions with regard to such records raised within such 3 year
period has been finally resolved, and will cause or require others whose
records are required for this purpose to do all of the same. If it is finally
determined that ITC is at any time in arrears for more than 30 days on
payment(s) totalling at least $25,000.00 owing to OSU under this License,
then, in addition to any other remedy available to Foundation, ITC will
reimburse OSU for OSU's actual and reasonable expenses in determining and
collecting such payments(s).
4.0 ITC shall begin Active Development of a Licensed Product within
five (5) years of the date of this agreement in those areas of commercial
interest.
4
OSU/ITC DECEMBER 26, 1996
4.1 Should no Active Development of a Licensed Product be in progress
within five (5) years from the date of this Agreement, this Agreement is
terminated unless specifically continued in writing and attached as Appendix B
to this Agreement.
4.2 Rights under this agreement shall be retained by ITC for the
non-hormonal antigens in the areas in which Active Development is continuing
and which are confirmed in writing and attached as Appendix B to his
Agreement.
4.2.1 If at least one (1) non-hormonal antigen for the treatment,
detection, diagnosis and/or prevention of cancer is under Active Development
within five (5) years of the date of this Agreement and recognized in writing
in Appendix B of this Agreement, the rights are extended for all non-hormonal
antigens for the treatment, detection, diagnosis and/or prevention of cancer
for an additional five years, for a total of ten (10) years from the date of
this Agreement.
4.2.2 If at least one (1) additional non-hormonal antigen, recognizing
the antigen in 4.2.1 as the first, for the treatment, detection, diagnosis
and/or prevention of cancer is under Active Development within ten (10) years
of the date of this Agreement and recognized in writing in Appendix B of this
Agreement the rights under this Agreement shall continue unless terminated
under sections 6.0-6.5 of this Agreement.
5.0 Subject to the terms and conditions of this License, ITC will
undertake, at the instance of WHO and on reasonable terms favorable to the
recipients, to supply Licensed Vaccine and other Licensed Product, for
distribution under the auspices of governmental and/or non-profit entities
for the ultimate purpose of preventing and/or treating hCG related problems
in humans in Developing Countries. ITC's obligations to WHO shall be limited
to the supply of Licensed Vaccine and Licensed Product in Developing
Countries for which the governmental authorities, or in which the aforesaid
non-profit entities, wish to have such Licensed Vaccine and/or Licensed
Product distributed. The foregoing shall not, however, be construed as an
obligation on the part of ITC to register the Licensed Vaccine and Licensed
Product in such Developing Countries. In Developing Countries where the
Licensed Vaccine and/or other Licensed Product is not registered, it shall be
the responsibility of the aforesaid governmental or non-profit entities to
ensure such registration prior to the distribution of the Licensed Vaccine
and/or other Licensed Product in such Developing Countries. ITC shall,
however, provide the said governmental and non-profit entities with its full
cooperation to permit such registration.
5.1 The supply referred to in section 5.0 above shall be at
manufacturing cost, including full allocation of overhead based on ITC's
overall production of the Licensed Vaccine or other Licensed Product, plus
the cost of liability insurance for the public sector of the Developing
Country, plus a xxxx-up of twenty-five percent (25%). No more than twenty
percent (20%) of ITC's gross capacity (as of the time for delivery) shall be
required to be devoted to such supply. In no event will this Section 5 impose
requirements on ITC's licensees. All supplies contemplated by section 5.0
above shall be subject to non-cancelable written orders for Licensed Vaccine
or other Licensed Product at least six months in advance of delivery and with
commercially acceptable credit risk for such supply.
5
OSU/ITC DECEMBER 26, 1996
5.2 ITC will also share information with, and accept recommendations
from, WHO on the same basis as OSU under section 4.3 above, insofar as
relevant to WHO's interest in making Licensed Vaccine and/or other Licensed
Product practically available for distribution in Developing Countries.
5.3 ITC's obligation to supply the Licensed Vaccine and other Licensed
Product in accordance with the provisions of this License shall be subject to
ITC having obtained all such governmental approvals and authorizations
including U. S. FDA approvals as may be required in the United States of
America to allow such production and supply. ITC shall use its best
reasonable efforts to obtain such approvals and authorizations as soon as
reasonably possible.
5.4 ITC's supply obligations shall not apply to any governmental or
non-profit entity through which ITC can show that Licensed Vaccine and/or
Licensed Product has become available for use in the private sector or for
use outside the field, in non-negligible quantities.
5.5 In the event ITC breaches any of its obligations under this Section
5, and, after receipt of a written notification to that effect from OSU,
fails to cure such breach within ninety (90) days, then ITC shall pay OSU an
additional one percent (1%) royalty on Net Sales which shall be remitted to
WHO or this License will be terminated.
5.6 ITC and OSU acknowledge that this Section 5 creates rights which are
important to the mission of WHO; however, OSU as a direct party to this
License retains the right to notify and enforce third party rights including
the right to terminate this agreement for non-performance by ITC as indicated
in Section 5.5.
5.7 ITC's supply obligations hereunder shall have an initial duration of
the earlier of (1) 10 (ten) years commencing on receipt of the first firm
orders for such supply or (2) termination of the License.
5.8 For the purpose of this License "distribution in the Public Sector"
shall mean any distribution constituting distribution on a social marketing
basis under the auspices of governmental or non-profit entities for the
ultimate purpose of preventing or treating cancer in humans in Developing
Countries.
6.0 This License shall become effective as of the date specified herein,
or if no such date is specified then as of the date upon which execution of
the License is completed by the last to sign this Agreement.
6.1 Unless earlier terminated by a party in accordance with applicable
law or the provisions hereof, this License shall remain in effect until ten
(10) years after every patent licensed hereunder has expired and every patent
application licensed hereunder has been finally granted, refused or
abandoned, or until thirty (30) years from the effective date of this
License, whichever occurs last, provided that any specific obligations of
payment or other performance that have matured prior to termination shall
survive. Furthermore, in case of termination of this agreement before the full
6
OSU/ITC December 26, 1996
term of this Agreement, all information and data relevant to obtaining or
maintaining requisite regulatory approval(s) for investigating, making and/or
marketing Licensed Product obtained by or subject to the control of ITC shall
be made available for such use by OSU and WHO, or their respective designees.
6.2 ITC may terminate the License upon written notice to OSU, provided
that such notice is given at least six months in advance of its effective
date if manufacture of Licensed Product for distribution and not solely for
research or trials has not begun as of the date of notice and at least one
year in advance of its effective date if manufacture for distribution has
begun as of the date of notice, unless OSU consents to shorter notice.
6.3 OSU may terminated this License for breach by ITC of a material term
or condition thereof by giving written notice to ITC of the breach(es) relied
upon and specifying the effective date, not less than 60 days after such
notice, when the termination shall be effective, but if within 60 days of
such notice ITC either
a) cures such breach(es) and gives written notice to OSU of such
cure or
b) provides a written explanation, acknowledged by OSU to be
acceptable, of why such breach(es) has(have) not in fact occurred,
then such termination shall not take effect. Unavailability of funds will not
be deemed to excuse delay or default of performance by ITC, except that a
reasonable delay will be excused insofar as the need for funds was not
reasonably foreseeable. ITC's insolvency, bankruptcy or assignment for the
protection of creditors shall be deemed a material breach by ITC.
6.4 No waiver of any breach(es) shall constitute or imply waiver of any
other breaches(es)
6.5 Any termination of this License shall not relieve either party of
obligations, nor deprive either party of rights, that
a) are provided for hereunder in the event of such termination,
b) relate to confidentiality of information or
c) relate to tender or receipt, respectively, of accrued reports,
royalties or expenses, including royalties escrowed pursuant to Sections 3
above insofar as the condition for their payment to OSU is subsequently
satisfied.
7. Neither OSU nor WHO makes any representations or warranties as to the
safety, efficacy, acceptability, or suitability for any use of any Licensed
Product or Licensed Service, or as to the accuracy or reliability of any
information provided by or for any term in connection with this License, or
as to the enforceability of any patent or other proprietary rights granted,
or as to the applicability of any other patent rights to the products or
activities contemplated herein, and in particular OSU AND WHO DISCLAIM ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY
PRODUCT, SERVICE OR
7
OSU/ITC December 26, 1996
INFORMATION PROVIDED BY OR UNDER THE AUTHORITY OF EITHER OF THEM UNDER OR IN
CONNECTION WITH THE LICENSE.
8. OSU will neither abandon, cancel, disclaim (other than a terminal
disclaimer necessary to secure allowance) nor dedicate, nor fail to prosecute
or maintain, any Licensed Patent, unless ITC is first given reasonable notice
and ITC fails to give timely request and authorization to OSU in writing or
by phone call confirmed by fax to continue prosecution and/or maintenance.
ITC will reimburse OSU the full amount of the actual and reasonable expenses
thereafter incurred for such continued prosecution and/or maintenance, net of
any reimbursement to or recovery by OSU of such expenses from any third
party. OSU will give ITC prompt notice of any such reimbursement or recovery
from a third party and will credit ITC's account accordingly. ITC will
reimburse for one-half (1/2) of OSU's actual and reasonable expenses of
obtaining and maintaining Licensed Patents, incurred with respect to Licensed
Patents listed in Appendix A after the effective date of this License or with
respect to any other Licensed Patent after the date of notice to ITC of such
other Licensed Patent under Section 1.5 above. Any amount due and payable to
OSU by ITC as reimbursement of such expenses, after applicable offsets and
credits, shall be paid to OSU within thirty days after receipt by ITC of
invoice therefor.
9. ITC and OSU will each promptly inform the other of any information of
which they become aware relating to possible infringement of any Licensed
Patent in the field(s) of ITC's exclusive rights under the within License.
Following consultation between them, either ITC or OSU may seek to xxxxx such
infringement by negotiation or by instituting suit, provided that:
a) ITC will not, without the prior express written consent of OSU, make
any admission of invalidity, unenforceability or unpatentability of, or
of fraud or inequitable conduct on the part of OSU, WHO or any employee,
agent or representative of any of them in connection with, any Licensed
Patent or any claim(s) thereof, and will take reasonable precautions
against providing grounds for declaratory judgment action by any third
party against OSU and/or WHO;
b) if ITC or OSU unilaterally institutes such suit it will, except as
otherwise provided herein or agreed at the time, bear the actual and
reasonable expenses of such suit and will keep the other party apprised
of the progress thereof, and the other party will provide reasonable
cooperation in support of such suit, including permitting its joinder as
a necessary or indispensable party in such suit;
c) if ITC and OSU jointly institute such suit they will bear the actual
and reasonable expenses of such suit equally and will confer and
cooperate with each other in the prosecution and/or settlement thereof;
and
d) out of any recovery, whether by negotiation, preceding suit,
settlement or judgment, OSU and ITC will each first be reimbursed pro
rata for their respective and actual and reasonable expenses, with any
balance divided equally between them.
8
OSU/ITC December 26, 1996
10. In determining the amount of any sale, royalty, expense,
reimbursement, offset or the like under this License, the fair value of any
payment, thing, right or forbearance, constituting or in lieu of all or part
thereof shall be included in such amount.
11. No provision of this Agreement shall reduce or limit the right
granted to ITC in the agreement dated March 12, 1996 nor shall Article 5.1 be
construed as requiring ITC to provide more than twenty percent (20%) of ITC's
gross capacity (at the time of delivery) of any one Licensed Product to
supply the public sector of Developing Countries.
12. In the event that either party is delayed or prevented from
performing any of the respective obligations under this License by reason of
acts of God, governmental requirements, fire, floods, strikes or because of
any other cause beyond the reasonable control of the party, then the time
period for performance of such obligations shall be extended for the period
of such delay.
13. Any notice, report or payment under this Agreement shall, if to ITC,
be sent to:
ImmunoTherapy Corporation
000 Xxxxxxx Xxxxxx Xxxx, Xxxxx 000
Xxxxxxx, Xxxxxxxxxx, 00000-0000
Attn. President
and, if to OSU, be sent to:
The Ohio State University Research Foundation
Office of Technology Transfer
0000 Xxxxx Xxxx
Xxxxxxxx, Xxxx 00000-0000
or to such other address for either party as that party may from time to time
give written notice of to the other.
14. ITC will not use the name of OSU without the express prior written
consent of OSU, or of WHO without the express prior written consent of WHO,
in any commercial promotion or advertising relating to the subject matter of
this License.
15. This License will be construed under the laws of the State of Ohio.
16. OSU will encourage any other licensees under the Licensed Patents to
make any improvements developed by them that may be applicable to the subject
of this License available to ITC on reasonable terms. Correspondingly ITC
will give good faith consideration to making any improvements developed by it
that may be applicable to the subject of any other licenses available to the
licensees on reasonable terms.
9
OSU/ITC December 26, 1996
17. This Agreement constitutes the entire agreement among the parties
relating to the subject matter thereof, and all prior negotiations,
representations, agreements and understandings are merged into, extinguished
by, and completely expressed by it.
AGREED TO AND ACCEPTED
The Ohio State University
By /s/ Xxxxx X. Xxxxxxxx Date 13 Jan 97
------------------------------------------------ ----------------------
Print Name/Title
The Ohio State University Research Foundation
By /s/ Xxxxx X. Xxxxx Date 3 Jan 97
------------------------------------------------ ----------------------
Print Name/Title
Immuno Therapy Corporation
By /s/ Xxxxxxx X. Xxxxxxxx Date 12/30/96
------------------------------------------------ ----------------------
Print Name/Title Xxxxxxx X. Xxxxxxxx
President/CEO
10
OSU/ITC
APPENDIX A
Patent Applications and Patents Covered by this Agreement.
U.S. PATENTS (OSU)
------------------
2-011-3(4) ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 05/936,876 Filed : 8-25-78
Patent No.: 4,201,770 Issued: 5-6-80
Expires : 5-6-97
2-011-3-3-3-3 ANTIGENIC MODIFICATION OF POLYPEPTIDES
-2
Serial No.: 06/112,628 Filed : 1-16-80
Patent No.: 4,302,386 Issued: 11-24-81
Expires : 11-24-98
2-011-3-3-3-3 ANTIGENIC MODIFICATION OF POLYPEPTIDES
-2-3
Serial No.: 06/323,690 Filed : 11-20-81
1. Patent No.: 4,384,995 Issued: 5-24-83
Expires : 5-24-2000
2-011-3-3-3-3 ANTIGENIC MODIFICATION OF POLYPEPTIDES
-2-3-3
Serial No.: 06/472,190 Filed : 3-4-83
Patent No.: 4,526,716 Issued: 7-2-85
Expires : 7-2-2002
2-011-3(4)-2-3(3) ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 06/667,863 Filed : 11-2-84
Patent No.: 4,691,006 Issued: 9-1-87
Expires : 9-1-2004
2-011-3(4)-2-3(3)- ANTIGENIC MODIFICATION OF POLYPEPTIDES
2 I
Serial No.: 07/073,570 Filed : 7-15-87
Patent No.: 4,767,842 Issued: 8-30-88
Expires : 8-30-2005
2-011-3(4)-2-3(3)- ANTIGENIC MODIFICATION OF POLYPEPTIDES
2 I
Serial No.: 07/073,769 Filed : 7-15-87
Patent No.: 4,762,913 Issued: 8-9-88
Expires : 8-9-2005
2-011-3(4)-2-3(4) ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 07/073,748 Filed : 7-15-87
Patent No.: 5,006,334 Issued: 4-9-91
Expires : 4-9-2008
11
OSU/ITC
FOREIGN PATENTS (OSU)
---------------------
2-011(83) AU ANTIGENIC MODIFICATION OF POLYPEPTIDES
Australia
Appl. No. : 17040/83 Filed : 5-18-83
Patent No.: 570004 Issued: 9-2-88
Expires : 5-18-99
2-011(83) GB- ANTIGENIC MODIFICATION OF POLYPEPTIDES
2 I
Great Britain Appl. No. : 8619232 Filed : 3-18-83
Patent No.: 2 178 041 Issued: 1-6-88
Expires : 3-18-2002
2-011(83) GR ANTIGENIC MODIFICATION OF POLYPEPTES
Greece
Appl. No. : 71441 Filed : 5-24-83
Patent No.: 79126 Issued: 10-2-84
Expires : 5-24-2003
2-011(83) IS ANTIGENIC MODIFICATION OF POLYPEPTES
Israel
Appl. No. : 68749 Filed : 5-20-83
Patent No.: 68749 Issued: 11-1-88
Expires : 5-20-2003
2A011(83) IS- ANTIGENIG MODIFICATION OF POLYPEPTIDES
2 I
Israel Appl. No. : 79093 Filed : 5-20-83
Patent No.: 79093 Issued: 11-1-88
Expires : 5-20-2003
2-011(83) IS- ANTIGENIC MODIFICATION OF POLYPEPTIDES
2 II
Israel Appl. No. : 82020 Filed : 5-20-83
Patent No.: 82020 Issued: 11-1-88
Expires : 5-20-2003
U.S. APPLICATIONS (OSU)
-----------------------
2-011-3(4)-2-3(4)- METHOD OF TREATMENT USING ANTIGENICALLY MODIFIED
-2-1 POLYPEPTIDES
Serial No.: 07/935,331 Filed : 8-26-92
Patent No.: Issued:
Expires :
2011-DIV 1 METHOD FOR TREATMENT OF ANTIGENITICAILY MODIFIED
POLYPEPTIDES
Serial No.: 08/466,445 Filed : 6-6-95
Patent No.: Issued:
Expires :
00
XXX/XXX
0000-XXX 2 METHOD FOR TREATMENT OF ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/469,689 Filed : 6-6-95
Patent No.: Issued:
Expires :
2011-DIV 3 METHOD FOR TREATMENT OF ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/468,716 Filed : 6-6-95
Patent No.: Issued:
Expires :
2011-DI 4 METHOD FOR TREATMENT OF ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/465,870 Filed : 6-6-95
Patent No.: Issued:
Expires :
2011-DIV 5 METHOD FOR TREATMENT OF ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/471,422 Filed : 6-6-95
Patent No.: Issued:
Expires :
2011-DIV 6 METHOD FOR TREATMENT OF ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/465,777 Filed : 6-6-95
Patent No.: Issued:
Expires :
2011-DIV 7 METHOD FOR TREATMENT OE ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/469,043 Filed : 6-6-95
Patent No.: Issued:
Expires :
2011-DIV 8 METHOD FOR TREATMENT OF ANTIGENICALLY MODIFIED
POLYPEPTIDES
Serial No.: 08/466,660 Filed : 6-6-95
Patent No.: Issued:
Expires :
13
OSU/ITC DECEMBER 26, 1996
U.S. PATENTS (OSURF)
0-000 XXXXXXXXX MODIFICATION OF POLYPEPTIDES
Serial No.: 06/804,642 Filed : 12-4-85
Patent No.: 4,713,366 Issued: 12-15-87
Expires : 12-4-2005*
2-056-3 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 07/086,401 Filed : 8-17-87
Patent No.: 4,855,285 Issued 8-8-89
Expires : 8-8-2006
U.S. APPLICATIONS (OSURF)
2-056-3-3-1 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 07/958,601 Filed : 10-6-92
Patent No.: Issued :
Expires :
2-056-3-3-3 VACCINES AND ANTIGENIC CONJUGATES
(from PCT)
Serial No.: 08/406,916 Filed : 3-27-95
Patent No.: Issued
Expires :
2056-DIV 1 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 08/471,002 Filed : 6-6-95
Patent No.: Issued :
Expires :
2056-DIV 2 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 08/465,694 Filed : 6-6-95
Patent No.: Issued
Expires :
2056-DIV 3 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 08/467,997 Filed : 6-6-95
Patent No.: Issued
Expires :
2056-DIV 4 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 08/470,744 Filed: 6-6-55
Patent No.: Issued
Expires
2056-DIV 5 ANTIGENIC MODIFICATION OF POLYPEPTIDES
14
OSU/ITC DECEMBER 26, 1996
Serial No.: 08/466,473 Filed: 6-6-95
Patent No.: Issued
Expires
2056-CONT 6 ANTIGENIC MODIFICATION OF POLYPEPTIDES
Serial No.: 08/467,569 Filed: 6-6-95
Patent No.: Issued
Expires
FOREIGN APPLICATIONS (OSURF)
2-056-3-3-3AU VACCINES AND ANTIGENIC CONJUGATES
Australia
(from PCT) Appl. No. : 28063/92 Filed 3-21-95
Patent No.: Issued
Expires
2-056-3-3-3CA VACCINES AND ANTIGENIC CONJUGATES
Canada
(from PCT) Appl. No. : 2,145,391 Filed 3-23-95
Patent No.: Issued
Expires
2-056-3-3-3EP VACCINES AND ANTIGENIC CONJUGATES
European Xxx.
(from PCT) Appl. No. : 92921753.7 Filed: 9-30-92
Patent No.: Issued:
Expires :
2-056-3-3-3JP VACCINES AND ANTIGENIC CONJUGATES
Japan
(from PCT) Appl. No. : 508977/94 Filed: 9-30-92
Patent No.: Issued :
Expires :
2-056-3-3-3KR VACCINES AND ANTIGENIC CONJUGATES
South Korea
Appl. No. : 1993-700712 Filed: 3-9-93
Patent No.: Issued :
Expires :
15
OSU/ITC DECEMBER 26, 0000
XXXXXXXX X
Non-Hormonal Antigens under Active Development Attachments Signed as
Recognized and Agreed To by the Parties)
16
